Stocks and Investing Stocks and Investing
Fri, August 5, 2022

Gena Wang Upgraded (BLUE) to Hold and Increased Target to $5 on, Aug 5th, 2022


Published on 2024-10-27 22:27:51 - WOPRAI, Gena Wang
  Print publication without navigation


Gena Wang of Barclays, Upgraded "bluebird bio, Inc." (BLUE) to Hold and Increased Target from $3 to $5 on, Aug 5th, 2022.

Gena has made no other calls on BLUE in the last 4 months.



There are 5 other peers that have a rating on BLUE. Out of the 5 peers that are also analyzing BLUE, 2 agree with Gena's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Yaron Werber of "Cowen & Co." Downgraded from Buy to Hold on, Wednesday, April 6th, 2022
  • Mani Foroohar of "SVB Leerink" Maintained at Hold with Decreased Target to $8 on, Wednesday, April 6th, 2022


These are the ratings of the 3 analyists that currently disagree with Gena


  • Dane Leone of "Raymond James" Upgraded from Hold to Buy and Held Target at $8 on, Tuesday, August 2nd, 2022
  • Salveen Richter of "Goldman Sachs" Maintained at Strong Sell with Decreased Target to $2 on, Tuesday, May 24th, 2022
  • Matthew Harrison of "Morgan Stanley" Maintained at Sell with Decreased Target to $3 on, Tuesday, May 17th, 2022
Contributing Sources